Filing Details

Accession Number:
0001126234-13-000101
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-06-12 07:20:30
Reporting Period:
2013-06-10
Filing Date:
2013-06-12
Accepted Time:
2013-06-12 07:20:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1126234 Newlink Genetics Corp (NLNK) Pharmaceutical Preparations (2834) 421491350
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1261262 Jr H Gordon Link C/O Newlink Genetics Corporation
2503 South Loop Dr., Suite 5100
Ames IA 50010
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-06-10 10,500 $2.10 16,913 No 4 M Direct
Common Stock Disposition 2013-06-10 1,103 $20.00 15,810 No 4 F Direct
Common Stock Disposition 2013-06-10 9,397 $20.00 6,413 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2013-06-10 10,500 $2.10 10,500 $2.10
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
66,239 2018-08-05 No 4 M Direct
Footnotes
  1. Represents a "net exercise" of outstanding stock options. The reporting person received 9,397 shares of common stock on net exercise of option to purchase 10,500 shares of common stock. The Reporting Person forfeited 1,103 shares of common stock underlying the option in payment of the exercise price, using a stock price from the sale of $20.00.
  2. The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on 10/1/2012.
  3. 1/4th of the shares vest on August 4, 2009, which is one year after the vesting commencement date. 1/48th of the shares vest monthly thereafter over the next three years.